NASDAQ$XBIT
XBiotech Inc · Q2 2024 earnings
Q2 2024 earnings · · Investor relations
Briefing
XBiotech Inc Q2 fiscal 2024: $13.0M net loss, $0.43 loss per share
for the year ended December 31, 2023 filed with the SEC on March 15, 2024, and under the heading “Risk Factors” and elsewhere in this Quarterly Report on Form 10-Q. (SEC accession 0001171843-24-004689)
- Net loss: $13.0M
- Diluted EPS: $-0.43
- Operating income: $-15.0M
Headline financials
Revenue & EPS history
XBiotech · Revenue · Quarterly
$0
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q2 2024
+0.3%
Avg return
Earnings day
+0.7%
Avg return
5 days after
+2.3%
Avg return
30 days after
44%
19 / 43 earnings
Positive
+13.5%
Q1 2016
Best reaction
-11.2%
Q1 2017
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | -2.6% | — | — | |
| Q3 2025 | -5.8% | -16.0% | -18.4% | |
| Q2 2025 | +5.7% | +7.7% | -7.4% | |
| Q1 2025 | -1.7% | -3.4% | -5.4% | |
| Q4 2024 | +4.5% | -4.8% | -7.1% | |
| Q3 2024 | -1.7% | -5.9% | -2.0% | |
| Q2 2024 | -2.4% | -7.9% | -1.8% | |
| Q4 2023 | +4.2% | +12.6% | +45.4% | |
| Q3 2023 | -0.4% | -3.7% | +5.4% | |
| Q2 2023 | -3.0% | -4.3% | -5.1% | |
| Q1 2023 | +2.4% | +1.8% | +66.2% | |
| Q4 2022 | +4.9% | +1.5% | +9.2% | |
| Q3 2022 | -1.4% | +1.1% | -9.9% | |
| Q2 2022 | -1.6% | -1.4% | -20.0% | |
| Q1 2022 | -5.0% | -9.6% | -7.5% | |
| Q4 2021 | +2.0% | +6.8% | -7.1% | |
| Q3 2021 | -4.2% | -7.3% | -25.2% | |
| Q2 2021 | +1.4% | -1.3% | -3.0% | |
| Q1 2021 | +2.8% | +0.1% | +0.3% | |
| Q4 2020 | -3.1% | -2.5% | -14.9% | |
| Q3 2020 | +5.1% | +5.3% | -1.1% | |
| Q2 2020 | +6.8% | +14.4% | +29.6% | |
| Q1 2020 | +0.9% | -9.3% | -10.0% | |
| Q4 2019 | -1.2% | -7.8% | +32.2% | |
| Q3 2019 | +2.9% | +12.6% | +77.6% | |
| Q2 2019 | -0.7% | +7.1% | +22.0% | |
| Q1 2019 | +3.3% | -2.6% | -17.9% | |
| Q4 2018 | -4.6% | +10.3% | -5.0% | |
| Q3 2018 | -0.5% | +3.7% | +17.3% | |
| Q2 2018 | +3.5% | +9.7% | -10.7% | |
| Q1 2018 | +0.0% | +3.3% | +1.9% | |
| Q4 2017 | +6.7% | +5.1% | +9.4% | |
| Q3 2017 | +2.0% | -0.2% | +16.5% | |
| Q2 2017 | -5.0% | +4.1% | +14.4% | |
| Q1 2017 | -11.2% | -10.7% | -68.2% | |
| Q4 2016 | +6.5% | +10.0% | +3.2% | |
| Q3 2016 | +10.3% | +9.1% | -6.7% | |
| Q2 2016 | -5.6% | -2.2% | -9.7% | |
| Q1 2016 | +13.5% | — | — | |
| Q4 2015 | -6.1% | — | — | |
| Q3 2015 | -7.0% | — | — | |
| Q2 2015 | -1.0% | — | — | |
| Q1 2015 | -1.5% | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2013 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro